Combination study of VB-111 with a checkpoint inhibitor in patients with lung cancer

Trial Profile

Combination study of VB-111 with a checkpoint inhibitor in patients with lung cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Ofranergene obadenovec (Primary)
  • Indications Lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Jun 2017 New trial record
    • 19 Jun 2017 According to a VBL Therapeutics media release, company plans to launch this study by year-end 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top